Literature DB >> 17268512

Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.

M W J C Jansen1, L Corral, V H J van der Velden, R Panzer-Grümayer, M Schrappe, A Schrauder, R Marschalek, C Meyer, M L den Boer, W J C Hop, M G Valsecchi, G Basso, A Biondi, R Pieters, J J M van Dongen.   

Abstract

The aim of this study was to identify immunobiological subgroups in 133 infant acute lymphoblastic leukemia (ALL) cases as assessed by their immunophenotype, immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangement pattern, and the presence of mixed lineage leukemia (MLL) rearrangements. About 70% of cases showed the pro-B-ALL immunophenotype, whereas the remaining cases were common ALL and pre-B-ALL. MLL translocations were found in 79% of infants, involving MLL-AF4 (41%), MLL-ENL (18%), MLL-AF9 (11%) or another MLL partner gene (10%). Detailed analysis of Ig/TCR rearrangement patterns revealed IGH, IGK and IGL rearrangements in 91, 21 and 13% of infants, respectively. Cross-lineage TCRD, TCRG and TCRB rearrangements were found in 46, 17 and 10% of cases, respectively. As compared to childhood precursor-B-ALL, Ig/TCR rearrangements in infant ALL were less frequent and more oligoclonal. MLL-AF4 and MLL-ENL-positive infants demonstrated immature rearrangements, whereas in MLL-AF9-positive leukemias more mature rearrangements predominated. The immature Ig/TCR pattern in infant ALL correlated with young age at diagnosis, CD10 negativity and predominantly with the presence and the type of MLL translocation. The high frequency of immature and oligoclonal Ig/TCR rearrangements is probably caused by early (prenatal) oncogenic transformation in immature B-lineage progenitor cells with germline Ig/TCR genes combined with a short latency period.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17268512     DOI: 10.1038/sj.leu.2404578

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  31 in total

1.  Characterization of CD22 expression in acute lymphoblastic leukemia.

Authors:  Nirali N Shah; Maryalice Stetler Stevenson; Constance M Yuan; Kelly Richards; Cindy Delbrook; Robert J Kreitman; Ira Pastan; Alan S Wayne
Journal:  Pediatr Blood Cancer       Date:  2015-03-01       Impact factor: 3.167

Review 2.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

Review 3.  Concise review: hematopoietic stem cell aging and the prospects for rejuvenation.

Authors:  Martin Wahlestedt; Cornelis Jan Pronk; David Bryder
Journal:  Stem Cells Transl Med       Date:  2014-12-29       Impact factor: 6.940

4.  Genetic variants modify susceptibility to leukemia in infants: a Children's Oncology Group report.

Authors:  Julie A Ross; Amy M Linabery; Crystal N Blommer; Erica K Langer; Logan G Spector; Joanne M Hilden; Nyla A Heerema; Gretchen A Radloff; Richard L Tower; Stella M Davies
Journal:  Pediatr Blood Cancer       Date:  2012-03-15       Impact factor: 3.167

5.  Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Huining Kang; Carla S Wilson; Richard C Harvey; I-Ming Chen; Maurice H Murphy; Susan R Atlas; Edward J Bedrick; Meenakshi Devidas; Andrew J Carroll; Blaine W Robinson; Ronald W Stam; Maria G Valsecchi; Rob Pieters; Nyla A Heerema; Joanne M Hilden; Carolyn A Felix; Gregory H Reaman; Bruce Camitta; Naomi Winick; William L Carroll; ZoAnn E Dreyer; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

6.  The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.

Authors:  P Garrido Castro; E H J van Roon; S S Pinhanços; L Trentin; P Schneider; M Kerstjens; G Te Kronnie; O Heidenreich; R Pieters; R W Stam
Journal:  Leukemia       Date:  2017-07-10       Impact factor: 11.528

Review 7.  Infant acute lymphoblastic leukemia: Lessons learned and future directions.

Authors:  Rob Pieters
Journal:  Curr Hematol Malig Rep       Date:  2009-07       Impact factor: 3.952

8.  Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature.

Authors:  Takeo Sarashina; Haruko Iwabuchi; Naoyuki Miyagawa; Masahiro Sekimizu; Tomoko Yokosuka; Kunio Fukuda; Satoshi Hamanoue; Fuminori Iwasaki; Shoko Goto; Masae Shiomi; Chihaya Imai; Hiroaki Goto
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

9.  MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children's Oncology Group (COG) study.

Authors:  Thien N Sam; John H Kersey; Amy M Linabery; Kimberly J Johnson; Nyla A Heerema; Joanne M Hilden; Stella M Davies; Gregory H Reaman; Julie A Ross
Journal:  Pediatr Blood Cancer       Date:  2011-07-28       Impact factor: 3.167

10.  Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity.

Authors:  Albert G Tsai; Haihui Lu; Sathees C Raghavan; Markus Muschen; Chih-Lin Hsieh; Michael R Lieber
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.